

Securing a Safe & Fair Marketplace.

#### PRESCRIPTION MONITORING PROGRAM

SNAP SHOT OF LEGAL CONTROLLED SUBSTANCE PRESCRIPTION USAGE THOUGHOUT CONNECTICUT


#### **Disclaimer**

All of the data reported by the PMP is compiled at specific points in time and captures only data currently entered at that time. The data values may subsequently be updated and may change over time as those updates occur. Accordingly, quarterly reported data may not perfectly match annually reported data. The data does not contain any information about the diagnosis and does not reflect the use intended by the prescriber.






#### **Controlled Substance Rx/Year**








### 2018 Prescriptions per Quarter








### **2018 Prescriptions by Drug Schedule**







# **Controlled Substance Prescription**Rate










# **2018 Patient Demographic Environment**








**Urban** 






# **Controlled Substance Prescription**Rate








### **2018 Payment Type of Prescriptions**








### 2018 New vs. Refill Prescriptions







### 2018 % Prescriptions > 90 MME vs. All






\*Morphine Milligram Equivalent (MME) is a standard metric used to compare the potencies of different opioid medications. A combination of medications with an MME of 90 or above is considered a level that would put a patient at increased risk for an overdose.




### **Opioid vs. Non-Opioid Prescriptions**








### **Opioid Prescriptions per Year**








### **Opiate Agonist Prescription Rate**








# **Opiate Partial Agonist Prescription Rate**








### **Opiate Agonist Prescription Rate**








# **Opiate Partial Agonist Prescription Rate**








# **Benzodiazepine Prescriptions per Year**







#### **Most Prescribed Controlled Substances**




**Drug Generic Name** 



\*Specifically, the drug dextroamphetamine sulf-saccharate/amphetamine sulfaspartate




### **Benzodiazepine Prescription Rate**







### **Benzodiazepine Prescription Rate**










# Connecticut Prescription Monitoring & Reporting System (CPMRS)

### Users Registered in the CPMRS per Year






<sup>1</sup>In June 2016, DCP switched to a new system so only 6 months of data is available for 2016. This data excludes requests done by prescribers through their electronic health record (EHR) integration with the CPMRS.



#### **CPMRS** User Searches per Year






<sup>1</sup>In June 2016, DCP switched to a new system so only 6 months of data is available for 2016. This data excludes requests done by prescribers through their electronic health record (EHR) integration with the CPMRS.




### CT Controlled Substance Registrations vs. CT Practitioners Writing at least 1 CS Prescription








# % of Prescribers Utilizing CPMRS who wrote at least 1 CS Prescription







### **Data Sharing States**







### **Prescription Monitoring Program**

#### **Director of Drug Control**

Rodrick Marriott, PharmD

#### **PMP Program Manager**

Scott Szalkiewicz, MPH, CHES

#### **Program Staff**

Luis Arroyo
Donna Damon
Debora Jones
Nana Kittiphane
Valerie Maignan, MPH

450 Columbus Boulevard Suite 901

Hartford, CT 06103 Phone: 860-713-6073

Email: dcp.pmp@ct.gov



